Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q15435

UPID:
PP1R7_HUMAN

ALTERNATIVE NAMES:
Protein phosphatase 1 regulatory subunit 22

ALTERNATIVE UPACC:
Q15435; B4DFD4; B5MCY6; Q9UQE5; Q9UQE6; Q9Y6K4

BACKGROUND:
The regulatory subunit of protein phosphatase 1, known alternatively as Protein phosphatase 1 regulatory subunit 22 or Protein phosphatase 1 regulatory subunit 7, is integral to the regulation of protein phosphatase 1. This enzyme's activity is essential for the regulation of key cellular activities, including glycogen metabolism, muscle contraction, and cell cycle progression. By controlling the phosphorylation state of various proteins, it influences critical cellular functions and signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Protein phosphatase 1 regulatory subunit 7 offers a promising avenue for the development of novel therapeutic approaches. Given its involvement in critical cellular processes, targeting this protein could lead to innovative treatments for conditions associated with its dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.